Policy & Compliance FDA Sends New Round of Warning Letters Over Compounded GLP-1 Marketing Claims
Key Takeaways The Food and Drug Administration (FDA) has intensified its scrutiny of the telehealth weight-loss market, publishing warning letters on June 16, 2026 to 25 companies for their marketing



